• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Elicio Therapeutics, Inc. - Common Stock (NQ:ELTX)

    10.75 -0.04 (-0.37%)
    Streaming Delayed Price Updated: 12:22 PM EDT, Oct 8, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 23,780
    Open 10.86
    Bid (Size) 10.66 (2)
    Ask (Size) 10.77 (2)
    Prev. Close 10.79
    Today's Range 10.53 - 10.87
    52wk Range 4.050 - 12.62
    Shares Outstanding 29,798,399
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Reports Inducement Grants
    From Elicio Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    +109.1%
    +109.1%
    1 Month
    -8.1%
    -8.1%
    3 Month
    +27.7%
    +27.7%
    6 Month
    +107.1%
    +107.1%
    1 Year
    +134.7%
    +134.7%

    More News

    Read More
    Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio (ELTX) Q2 Loss Beats Estimates
    Via The Motley Fool
    Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Secures $10 Million in Financing
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
    From Elicio Therapeutics Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Elicio Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Elicio Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Elicio Therapeutics, Inc. - Common Stock trade on?
    Elicio Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Elicio Therapeutics, Inc. - Common Stock?
    The ticker symbol for Elicio Therapeutics, Inc. - Common Stock is ELTX on the Nasdaq Stock Market
    What is the current price of Elicio Therapeutics, Inc. - Common Stock?
    The current price of Elicio Therapeutics, Inc. - Common Stock is 10.75
    When was Elicio Therapeutics, Inc. - Common Stock last traded?
    The last trade of Elicio Therapeutics, Inc. - Common Stock was at 10/08/25 12:22 PM ET
    What is the market capitalization of Elicio Therapeutics, Inc. - Common Stock?
    The market capitalization of Elicio Therapeutics, Inc. - Common Stock is 320.33M
    How many shares of Elicio Therapeutics, Inc. - Common Stock are outstanding?
    Elicio Therapeutics, Inc. - Common Stock has 320M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.